Last reviewed · How we verify

Bupivacaine 0.125%

Shanghai Pulmonary Hospital, Shanghai, China · FDA-approved active Small molecule

Bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses.

Bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses. Used for Local and regional anesthesia for infiltration, nerve block, and epidural/spinal procedures.

At a glance

Generic nameBupivacaine 0.125%
Also known asPlain marcaine, Marcaine
SponsorShanghai Pulmonary Hospital, Shanghai, China
Drug classLocal anesthetic
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Bupivacaine reversibly binds to and inactivates voltage-gated sodium channels on the inner surface of nerve cell membranes, thereby preventing depolarization and action potential propagation. This results in a loss of sensation in the infiltrated tissue. The drug has a relatively long duration of action compared to other local anesthetics due to its high lipophilicity and protein binding.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: